Scorpius Holdings (Scorpius Holdings) ROCE % : -55.21% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Scorpius Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Scorpius Holdings's annualized ROCE % for the quarter that ended in Dec. 2023 was -55.21%.

Scorpius Holdings ROCE % Historical Data

The historical data trend for Scorpius Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scorpius Holdings ROCE % Chart

Scorpius Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-76.95

-36.11

-26.33

-40.88

-65.29

Scorpius Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-62.75	-69.96	-82.61	-80.24	-55.21

Scorpius Holdings ROCE % Calculation

Scorpius Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-41.557	/	( ( (104.397 - 18.037)	+	(51.038 - 10.1) )	/ 2 )
	=	-41.557	/	( (86.36	+	40.938)	/ 2 )
	=	-41.557	/	63.649
	=	-65.29 %

Scorpius Holdings's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-23.84	/	( ( (69.915 - 24.488)	+	(51.038 - 10.1) )	/ 2 )
	=	-23.84	/	( ( 45.427	+	40.938 )	/ 2 )
	=	-23.84	/	43.1825
	=	-55.21 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Scorpius Holdings (AMEX:SCPX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Scorpius Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Scorpius Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Scorpius Holdings (Scorpius Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scorpius Holdings Inc (AMEX:SCPX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

1HB:Germany

Address

627 Davis Drive, Suite 300, Morrisville, NC, USA, 27560

Website

https://www.nighthawkbio.com

NightHawk Biosciences Inc is a commercial-stage company with a fully integrated ecosystem to accelerate the discovery and development of novel therapies that arm the immune system. By leveraging its proprietary platforms, the company is advancing its first-in-class product portfolio with a focus on cancer and inflammatory and infectious diseases. Its current pipeline has categories: Oncology, immunology and molecular biology.

Executives

Prendergast John K A	director	ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017
Jeffrey Alan Wolf	director, officer: Chief Executive Officer	3985 RESEARCH PARK DRIVE, ANN ARBOR MI 48108
Smith Edward B Iii	director	C/O BRIGHTLINE CAPITAL MANAGEMENT, LLC, 1120 AVE OF THE AMERICAS, SUITE 1505, NEW YORK NY 10036
William L. Ostrander	officer: CFO/Corp Secy	801 CAPITOLA DRIVE, SUITE 12, DURHAM NC 27713
John J Monahan	director
Robert James Jakobs	officer: VP Finance/Controller/Secty	PO BOX 14487, DURHAM NC 27709
Jeff Tobin Hutchins	officer: Chief Scientific Officer	15823 S. 4210 RD., CLAREMORE OK 74017
Ann A Rosar	officer: VP of Finance and Controller	C/O 801 CAPITOLA DRIVE, DURHAM NC 27713
Michael Kharitonov	director	100 EUROPA DRIVE, CHAPEL HILL NC 27517
Timothy J Creech	officer: Chief Financial Officer	C/O TRIMERIS, INC., 3518 WESTGATE DR. SUITE 300, DURHAM NC 27707
Stephen J. Dipalma	officer: Interim CFO	C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Aristar Heat, Llc	10 percent owner	1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Aristar Capital Management, Llc	10 percent owner	1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Aristar Capital Management Gp, Llc	10 percent owner	1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Taylor Schreiber	officer: Vice President of Research	100 EUROPA DRIVE, CHAPEL HILL NC 27517